Highlights:

• Smart Sensor Wearables Redefining Data Capture and Analysis
• Proprietary & Patented Neural Network Technology
• Allowing Life Sciences Researchers to harness rich, previously inaccessible data

VICTORIA, BC / ACCESSWIRE / January 23, 2024 / AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a leading company committed to acquiring and advancing Artificial Intelligence/Machine Learning technologies that address urgent societal needs, is pleased to report that it has received the following press release from its majority-owned subsidiary, Health Gauge Inc.:

Health Gauge Inc. proudly announces the launch of its innovative product, "The Pulse Whisperer" for Biometric Raw Signal Data. The Pulse Whisperer is a powerful tool designed for use by Life Science Researchers, providing them with unprecedented access to the raw biometric signals captured from smart sensor wearables, as well as the ability to utilize the raw data to help improve health outcomes through Health Gauge's unique and comprehensive suite of products. In a significant departure from conventional wearables like Apple Watches and FitBits, The Pulse Whisperer product suite encompasses Health Gauge's Smart Sensor Wearables, Device Firmware, SDK & APIs, and licensed access to Health Gauge's Proprietary and Patented Neural Network technology, all coupled with Health Gauge's scalable Biometric Platform for Life Sciences. Researchers can now harness rich, previously inaccessible data, opening new frontiers in health research.

Paul Duffy, CEO of AI/ML Innovations Inc., expressed enthusiasm, "The Pulse Whisperer marks an important moment in health tech innovation. By providing researchers with unparalleled access to raw biometric signals, we empower them to delve deeper into the intricacies of human health. This aligns with our mission at AI/ML Innovations Inc. to advance technologies that address urgent societal needs". Mr. Duffy continued, "Feedback indicates that there is widespread need within the medical community for a product suite such as The Pulse Whisperer. We anticipate that early adopters to this product suite will include Life Sciences and Medical Researchers, Educational and Academic Research communities, Healthcare Technology Developers, Data Scientists in Healthcare, Biomedical Engineers, Pharmaceutical Companies and Government and Health Policy Makers."

Real-Time Monitoring[1]: "With the competitive Internet of Medical Things (IoMT) market anticipated to grow to a global value of $187bn by 2028, the widespread adoption of interconnected devices and wearables that collect biometric data seems assured. Smartwatches and fitness trackers are just the first waves of technologies that are able to provide biometric research professionals with the ability to continuously monitor trial participants' vital signs, sleep patterns, and physical activity. The data science applications of the IoMT and real-time monitoring are immense. Large-scale data collection will allow researchers to aggregate and parse through vast amounts of biometric information, creating opportunities to improve healthcare outcomes and service provision across entire populations and the identification of disease patterns and trends that can be quickly responded to before they are spread too widely." (Source: Warman O'Brien 10:08:23)

Bruce Matichuk, Co-founder and CTO of Health Gauge Inc., added, "The Pulse Whisperer reflects our commitment to pushing the boundaries of what is possible in health technology. It's not just a product; it's a gateway to a new era of understanding and leveraging biometric data for transformative research."

About Health Gauge https://www.healthgauge.com/

Health Gauge, a majority-owned subsidiary of AI/ML Innovations Inc., is at the forefront of revolutionizing healthcare through the power of Health Intelligence. With a commitment to leveraging technology for human well-being, Health Gauge provides cutting-edge solutions for personalized health insights.

About AI/ML Innovations Inc. https://aiml-innovations.com/

AI/ML Innovations Inc. has realigned its business operations to capitalize on the burgeoning fields of artificial intelligence (AI) and machine learning (ML), with an initial investment focus on emerging digital health and wellbeing companies that leverage AI, ML, cloud computing and digital platforms to drive transformative healthcare management solutions and precision support delivery across the health continuum. Through strategic partnerships with Health Gauge (95.2% owned by AIML), Tech2Heal (up to 22% ownership rights, with 12.44% currently owned by AIML), AI Rx Inc. (70% owned by AIML) and other planned accretive investments, the Company continues to capitalize on expanding growth areas, to the benefit of all the Company's stakeholders. AI/ML's shares are traded on the Canadian Securities Exchange under the symbol "AIML", the OTCQB Venture Market under "AIMLF", and the Frankfurt Stock Exchange under "42FB".

On behalf of the Board of Directors
Tim Daniels, Executive Chairman

For more information about AI/ML Innovations:

For detailed information please see AI/ML's website or the Company's filed documents at www.sedarplus.ca

For further information, contact: Blake Fallis at (778) 405-0882 or info@aiml-innovations.com

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

For AI/ML Innovations Investors

Certain statements made in this press release that are not based on historical information are forward-looking statements that involve substantial known and unknown risks and uncertainties. This press release contains express or implied forward-looking statements relating to, among other things, AI/ML Innovations' expectations concerning management's plans, objectives, and strategies, including strategies for defending the Company's intellectual property. These statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. AI/ML Innovations Inc. undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events, or circumstances or otherwise except as expressly required by applicable securities law. Further information regarding the uncertainties and risks can be found in the disclosure documents filed by AI/ML with the securities regulatory authorities, available at www.sedar.com.